


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+26.64%
+5.29%
-16.76%
+16.46%
-13.51%
ANVS
Annovis Bio
$2.37
ANVS Price Performance
$2.79 (-15.05%)
$3.38 (-29.88%)
$2.19 (+8.22%)
$1.69 (+40.24%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
![]()
ANVS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ANVS Street Sentiment is extremely bullish and have negative views on the near-term outlook
ANVS has Extreme risk level
Risks Indicators

Beta greater than 1.0

Price under $5

Low volume

High volatilty

What is ANVS current stock price?
What are ANVS stock strengths?
What is ANVS Risk Level?
What is ANVS market cap and volume?
What is ANVS current Stock IQ?
Should I buy ANVS stock right now?
Is ANVS a Strong Buy right now?
What does a 'Strong Buy' rating mean for ANVS?
What does a 'Strong Sell' rating mean for ANVS?
What factors influence ANVS's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+26.64%
+5.29%
-16.76%
+16.46%
-13.51%
ANVS
Annovis Bio
Current Price
$2.37

ANVS Price Performance
$2.79 (-15.05%)
$3.38 (-29.88%)
$2.19 (+8.22%)
$1.69 (+40.24%)
ANVS Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
![]()
ANVS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ANVS Street Sentiment is extremely bullish and have negative views on the near-term outlook
ANVS has Extreme risk level
Risks Indicators

Beta greater than 1.0

Price under $5

Low volume

High volatilty

ANVS Stock IQ
Stock Insights
Not Enough Information
ANVS Latest Analysis
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimers Disease. MALVERN Pa. Feb. 12 2026 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) (Annovis or the Company) a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD) today announced that an independent Data and Safety Monitoring Board (DSMB) has issued a positive recommend
Thu Feb 12, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ANVS Stock trends
ANVS Stock performance
ANVS Stock analysis
ANVS investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.